Beijing Jinchengtaier Pharmaceutical Co., Ltd.

Primary Objective: To investigate the pharmacokinetic behavior of the test formulation, estradiol-dydrogesterone tablets (strength: estradiol 0.5 mg/dydrogesterone 2.5 mg; manufacturer: Beijing Jincheng Tai'er Pharmaceutical Co., Ltd.), and the reference formulation, estradiol-dydrogesterone tablets (trade name: Femoston-conti; strength: estradiol 0.5 mg/dydrogesterone 2.5 mg; licensee: Mylan Products Ltd., manufacturer: Abbott Biologicals B.V.), in healthy postmenopausal women in China under fasting conditions, and to evaluate the bioequivalence of the two formulations. Secondary Objective: To evaluate the safety of the two formulations of estradiol-dydrogesterone tablets after single oral administration under fasting conditions in healthy postmenopausal women in China.

Primary objective: To evaluate the clinical efficacy of nifuratel-nystatin vaginal soft capsules compared to the original control drug (trade name: Maimicom®) in the treatment of vaginitis. Secondary objective: To evaluate the safety of nifuratel-nystatin vaginal soft capsules in the treatment of vaginitis.

Primary Study Objectives To investigate the pharmacokinetic behavior of the test formulation, estradiol dydrogesterone tablets (strength: estradiol 0.5 mg/dydrogesterone 2.5 mg; manufacturer: Beijing Jincheng Taier Pharmaceutical Co., Ltd.), and the reference formulation, estradiol dydrogesterone tablets (trade name: Femoston-conti, strength: estradiol 0.5 mg/dydrogesterone 2.5 mg; licensee: Mylan Products Ltd, manufacturer: Abbott Biologicals B.V.), in healthy Chinese postmenopausal women following single oral administration in the fasting and fed states. The aim was to evaluate the bioequivalence of the two formulations of estradiol dydrogesterone tablets in healthy Chinese postmenopausal women following single oral administration in the fasting and fed states. Secondary Study Objectives To evaluate the safety of the two formulations of estradiol dydrogesterone tablets in healthy Chinese postmenopausal women following single oral administration in the fasting and fed states.